The recurrent inhibition of the soleus alpha-motoneurons at rest, evaluated by a specially designed method of paired H reflexes, was estimated in 10 patients with spastic paraparesis. In three of these patients, Renshaw cell activity produced inhibition of the corresponding alphamotor neurons comparable to that obtained in normal subjects, while the inhibition was reduced in five and absent in two. The effects of intravenously administered L-acetylcarnitine on the activity of Renshaw cells were studied in these patients. In all patients except the two with no evidence of recurrent inhibition, L-acetylcarnitine was found to significantly increase the amount of recurrent inhibition. Its effect became evident at about 30 minutes, reached a maximum around 50 minutes and vanished about 70 minutes from the onset of administration. A significant correlation was found between Renshaw cell activity and the ability of the drug to increase it. L-acetylcarnitine appeared to act specifically by enhancing recurrent inhibition, since no variation in the excitability of the monosynaptic reflex arc was observed.
patients, Renshaw cell activity produced inhibition of the corresponding alphamotor neurons comparable to that obtained in normal subjects, while the inhibition was reduced in five and absent in two. The effects of intravenously administered L-acetylcarnitine on the activity of Renshaw cells were studied in these patients. In all patients except the two with no evidence of recurrent inhibition, L-acetylcarnitine was found to significantly increase the amount of recurrent inhibition. Its effect became evident at about 30 minutes, reached a maximum around 50 minutes and vanished about 70 minutes from the onset of administration. A significant correlation was found between Renshaw cell activity and the ability of the drug to increase it. L-acetylcarnitine appeared to act specifically by enhancing recurrent inhibition, since no variation in the excitability of the monosynaptic reflex arc was observed. Recurrent inhibition, first described by Renshaw,' is mediated by axon collaterals of motor neurons (MNs) projecting to Renshaw cell (RC) inhibitory interneurons, which in turn project back to alpha-2" and gamma -5 MNs, Ia inhibitory interneurons6 and other RCs.7 One of the suggested roles for RC is as a variable gain regulator of MN output from descending fibre inputs. 8 This possible role in motor control has been particularly researched in normal9 and spastic subjects.""2 From the latter studies it can be inferred that supraspinal control of RCs was lacking during voluntary contraction, while recurrent inhibition at rest, if it changed at all, was decreased only in a limited number of patients.
Although current evidence does not support the idea that exaggeration of passively induced stretch reflexes in spastic patients may be related to a decrement in RC activity, it is reasonable to hypothesise that strengthening of the inhibitory activity of RCs could contribute to reducing the hyperactive stretch reflexes in these patients.
Preliminary results'3 have demonstrated that the intravenous administration of L-acetylcarnitine (L-AC), a well-known cholinomimetic drug"4 is capable of increasing the recurrent inhibition of soleus MNs in normal subjects. It was therefore of particular interest to study the effects of this drug on recurrent inhibition in spastic subjects.
Materials and methods Experiments were performed on 10 patients (eight males and two females, aged 13-58 years) who gave their informed consent after agreement from the local Ethical Committee. They were selected from a population of 17 subjects that participated in a recent investigation of the activity of soleus-coupled RCs in spasticity of spinal origin.'2 Of the original 17 patients, four were excluded from this study because they were unwilling to enter an acute pharmacological trial and three because of protocol noncompliance.
The new population presented with spastic paraparesis, its duration ranging from two to 25 years. The clinical picture was very similar in all patients, differing only in its severity: a degree of paresis and increased tendon jerk reflexes and tone were present in both lower limbs. One patient (Case 1 in the table) had a complete post-traumatic transection of the cord at low thoracic level; another (Case 2) had a compressive myelopathy from intervertebral disc protrusion at C5-C6; the remaining eight patients suffered from hereditary spastic paraparesis of Strumpell-Lorrain (Cases 3-10): the diagnosis was based on inheritance, lack of either electromyographic alterations of the peripheral nervous system or changes in brain computerised tomography (CT) and/or magnetic resonance imaging (MRI) scans. (See  table.) Method of estimating recurrent inhibition The subjects were seated on an examination chair, the knee and ankle joint at 110 and 90 deg respectively. The electromyographic activity of the soleus was recorded through surface electrodes set 2 cm apart, placed posteriorly on the lower third of the leg. The soleus H reflex was obtained by stimulating the tibial nerve at the popliteal fossa with rectangular pulses of 1 ms duration. The same unipolar electrode provided the conditioning and test stimuli.
Recurrent inhibition was evaluated by the method originally developed by Bussel and Pierrot-Deseilligny'5 and extensively described L-Acetylcarnitine (Nicetile®) was obtained from Sigma-Tau (Pomezia, Italy) 2000 mg of the drug were dissolved in a volume of 100 ml of 0'9% saline solution. At the beginning of the experiments, two iv infusion sets were prepared, connected to the patient via a twoway tap. The first bottle contained saline, the second the solution of L-AC. A continuous iv infusion of saline was started after setting the appropriate stimulation parameters. L-AC was then administered for 11-17 minutes (mean after which saline infusion was resumed.
It is important to stress that, although the order of treatment (saline, L-AC, saline) was constant, the patients could not realise when L-AC replaced saline and vice versa. Before, during and after L-AC administration, HI and H' reflexes were randomly evoked.
The amplitude of H reflexes was automatically measured (peak to peak) by com Figure 1A illustrates the typical pattern of variations in the H' test reflex amplitude as the HI conditioning reflex amplitude was increased by augmenting the strength of the S1 stimulus in a normal subject. At low HI reflex amplitude, the H' reflex closely followed HI up to a specific value (H' max) beyond which, as the HI continued to increase, there was a gradual decrease in the H' reflex amplitude. To decide whether the changes in H' reflex produced by L-AC were related to the control H' amplitude (that is, before L-AC administration), we plotted the maximal amounts of inhibition induced by L-AC versus the H' amplitude measured before administering the drug for each single patient. Figure 6 shows that there is a clear-cut and significant regression between the two variables. Assuming that the ratio H'/Hl in part reflects the amount of recurrent inhibition, it becomes apparent that the ability of the drug to decrease the H' amplitude is significantly dependent on the level of RC activity before L-AC administration in each subject.
Control experiments
Saline solution alone was administered in three patients (Cases 5, 7 and 6 see table). In fig 7, the 40 '' effects of L-AC ( fig 7A) and of saline ( fig 7B) on H' amplitude in Case 5 are compared. In no case did saline produce significant changes in the amplitude of the H' reflexes.
The possibility was also considered that the lack of effect of L-AC on the HI conditioning reflex could, in part, depend on its being of greater amplitude than H'. It is in fact known that the susceptibility to conditioning events of H reflexes is partly dependent on their size.'7 *0 Therefore, the effect of L-AC on unconditioned H reflexes, of amplitude equal to the H' control values, was tested in one patient (Case 6). No significant effect of the drug on unconditioned H reflexes of such amplitude -i---. was observed. 
P1
A burning sensation at the injection site was reported in some cases. Thus, we can hypothesise that an increase in recurrent inhibition is the main factor responsible for the depression of the H' amplitude produced by L-AC. This conclusion is strengthened by the significant correlation between the amount of H' inhibition produced by the drug and the level of RC activity before L-AC administration. The fact that the lower the recurrent inhibition, the less the drug is effective, indirectly supports the hypothesis that spastic subjects with a "straight line" pattern of H' variations lack recurrent inhibition.
Discussion
A further observation is prompted by the fact that L-AC is capable of enhancing recurrent inhibition also in patients with a "bell-shaped" pattern, in whom RC activity is supposed to be increased.'0 This indicates that there is still margin for additional increases in RC activity even in these cases. The possibility of strengthening such inhibitory activity may have some weight in resetting the balance between excitatory and inhibitory inputs to spinal MNs in spastic patients.
It must be stressed that the patients selected for this study represent a fairly homogeneous model of spasticity in that the spinal cord was the principal site of disease and the nature of spasticity was similar among the subjects. Since spasticity can arise from a multitude of lesions and its characteristics depend heavily on the precise localisation and combination of lesions, our results might not be generalised.
It is worth emphasising that the effects of L-AC on recurrent inhibition were also observed in a patient with complete transection of the cord at low thoracic level. This suggests that the drug exerts its action directly at spinal level.
Our conclusion that the effects of L-AC on the H' test reflex result from an increase in RC activity is coherent with the demonstration that these interneurons have both nicotinic and muscarinic excitatory receptors'8 which may be activated by systemic administration of blood-brain barrier-penetrating cholinergic agonists. 9
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